Rivaroxaban Concept

subject area of

• A Replacement for Warfarin  Academic Article
• A logical approach to surgical thromboprophylaxis  Academic Article
• A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment  Academic Article
• A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban  Academic Article
• Accumulating data on rivaroxaban for venous thromboembolism in clinical practice  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Advances in Antithrombotic Therapy  Academic Article
• Advances in the management of venous thromboembolism.  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding  Academic Article
• An assay to measure levels of factor Xa inhibitors in blood and plasma  Academic Article
• Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study  Academic Article
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Academic Article
• Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?  Academic Article
• Antiplatelet therapy in the management of atherothrombosis: recent clinical advances  Academic Article
• Antithrombotic Agents  Academic Article
• Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty  Academic Article
• Assays for Measuring Rivaroxaban: Their Suitability and Limitations  Academic Article
• Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes  Academic Article
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation  Academic Article
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism  Academic Article
• Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism  Academic Article
• Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source  Academic Article
• BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study  Academic Article
• Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach  Academic Article
• Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty  Academic Article
• Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin  Academic Article
• Beyond Unfractionated Heparin and Warfarin  Academic Article
• Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study  Academic Article
• Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience  Academic Article
• Bleeding with direct oral anticoagulants vs warfarin: clinical experience  Academic Article
• Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design  Academic Article
• Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment  Academic Article
• COMPASS for Vascular Surgeons  Academic Article
• Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF  Academic Article
• Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial  Academic Article
• Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials  Academic Article
• Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications  Academic Article
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Academic Article
• Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study  Academic Article
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Academic Article
• Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers  Academic Article
• Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2)  Academic Article
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Academic Article
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Academic Article
• Design of the rivaroxaban for heparin-induced thrombocytopenia study  Academic Article
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Academic Article
• Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Academic Article
• Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review  Academic Article
• Direct oral anticoagulants: evidence and unresolved issues  Academic Article
• Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis  Academic Article
• Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism  Academic Article
• Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state  Academic Article
• Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism  Academic Article
• Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism  Academic Article
• Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1  Academic Article
• Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry  Academic Article
• External applicability of the COMPASS trial: the Western Denmark Heart Registry  Academic Article
• Factor Xa and thrombin as targets for new oral anticoagulants  Academic Article
• Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban  Academic Article
• Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Global Prospective Safety Analysis of Rivaroxaban  Academic Article
• Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis  Academic Article
• High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source  Academic Article
• Higher-risk APS: do we dare to DOAC?  Academic Article
• How I treat heavy menstrual bleeding associated with anticoagulants  Academic Article
• How I treat target-specific oral anticoagulant–associated bleeding  Academic Article
• How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland  Academic Article
• Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban  Academic Article
• Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE  Academic Article
• Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy  Academic Article
• In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days  Academic Article
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Academic Article
• Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome  Academic Article
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Academic Article
• Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Academic Article
• Laboratory measurement of the direct oral anticoagulants  Academic Article
• Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply  Academic Article
• Less menorrhagia for women with VTE  Academic Article
• Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials  Academic Article
• Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS  Academic Article
• Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease  Academic Article
• Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy  Academic Article
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• Monitoring the anticoagulant effect after a massive rivaroxaban overdose  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• New Anticoagulants for Atrial Fibrillation  Academic Article
• New Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• New Anticoagulants for the Prevention of Thromboembolism  Academic Article
• New Antithrombotic Drugs: Potential for Use in Oncology  Academic Article
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants and oculoplastic surgery  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty  Academic Article
• New oral anticoagulants in elderly patients  Academic Article
• New oral anticoagulants: not quite there yet  Academic Article
• New oral anticoagulants: which one should my patient use?  Academic Article
• Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study  Academic Article
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Academic Article
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Academic Article
• Novel oral anticoagulants in gastroenterology practice  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants  Academic Article
• Oral Anticoagulant Therapy  Academic Article
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Academic Article
• Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism  Academic Article
• Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives  Academic Article
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease  Academic Article
• Oral factor Xa inhibitors and risk of subdural hematoma  Academic Article
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Academic Article
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases  Academic Article
• Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study  Academic Article
• Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study  Academic Article
• Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation  Academic Article
• Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease  Academic Article
• Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial  Academic Article
• Patients with Peripheral Artery Disease in the COMPASS Trial  Academic Article
• Perioperative management of patients who are receiving a novel oral anticoagulant  Academic Article
• Periprocedural Management of Oral Anticoagulation  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery  Academic Article
• Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients  Academic Article
• Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial  Academic Article
• Potential of new anticoagulants in patients with cancer  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study  Academic Article
• Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study  Academic Article
• Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial  Academic Article
• Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial  Academic Article
• Procoagulants for management of bleeding with the new oral anticoagulants  Academic Article
• Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study  Academic Article
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Academic Article
• Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery  Academic Article
• Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial  Academic Article
• Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS  Academic Article
• Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation  Academic Article
• Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism  Academic Article
• Reply  Academic Article
• Reply  Academic Article
• Reply  Academic Article
• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial  Academic Article
• Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants  Academic Article
• Risk of recurrent venous thromboembolism according to baseline risk factor profiles  Academic Article
• Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial  Academic Article
• Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction  Academic Article
• Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease  Academic Article
• Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios  Academic Article
• Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation  Academic Article
• Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography  Academic Article
• Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial  Academic Article
• Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions  Academic Article
• Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial  Academic Article
• Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline  Academic Article
• Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source  Academic Article
• Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice  Academic Article
• Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness  Academic Article
• Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer  Academic Article
• Rivaroxaban for prevention and treatment of venous thromboembolism  Academic Article
• Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial  Academic Article
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Academic Article
• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty  Academic Article
• Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies  Academic Article
• Rivaroxaban for treatment of HIT: A riveting first experience  Academic Article
• Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study  Academic Article
• Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?  Academic Article
• Rivaroxaban in Peripheral Artery Disease after Revascularization  Academic Article
• Rivaroxaban in Stable Cardiovascular Disease  Academic Article
• Rivaroxaban in treatment refractory heparin-induced thrombocytopenia  Academic Article
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism  Academic Article
• Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial  Academic Article
• Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition  Academic Article
• Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers  Academic Article
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin after total knee arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial  Academic Article
• Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study  Academic Article
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease  Academic Article
• Rivaroxaban with or without aspirin for prevention of cardiovascular disease  Academic Article
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial  Academic Article
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Academic Article
• Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion  Academic Article
• Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study  Academic Article
• Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin  Academic Article
• Selective factor Xa inhibition for thromboprophylaxis  Academic Article
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment  Academic Article
• Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial  Academic Article
• Stroke Outcomes in the COMPASS Trial  Academic Article
• Stroke Prevention in Atrial Fibrillation  Academic Article
• Stroke prevention in atrial fibrillation: Closing the gap  Academic Article
• Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease  Academic Article
• The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population  Academic Article
• The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation  Academic Article
• The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE  Academic Article
• The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations  Academic Article
• The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial  Academic Article
• The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale  Academic Article
• The effects of rivaroxaban on the complications of surgery after total hip or knee replacement  Academic Article
• The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study  Academic Article
• The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients  Academic Article
• The top 4 advances in antithrombotic care in the last year  Academic Article
• Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies  Academic Article
• Treatment of venous thromboembolism with dabigatran  Academic Article
• Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014  Academic Article
• Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism  Academic Article
• Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study  Academic Article
• Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• What is the effect of rivaroxaban on routine coagulation tests?  Academic Article
• XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America  Academic Article
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation  Academic Article
• XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation  Academic Article
• Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both  Academic Article